For participants to identify a face-name pair correctly as intact from study at the time of test, an associative memory for the face and the name must be formed, thus the II trials coded for associative memory.
All players were free from injury at the time of testing and were asked to maintain their normal diet throughout the competition; water was available ad libitum throughout.
Time to clinical manifestation was calculated as years remaining from subjects' current age at the time of testing to the calculated age of onset accordingly to their polyglutamine expansion size.
All patients had been discharged from hospital, were stable at the time of testing and were tested a minimum of 1.5 years post-stroke (85% were tested 3.5 years or more post-stroke; mean 7 years).
Experimental comparisons between treatments (i.e., direct competition and mate choice experiments, below) were performed on cage-born offspring from both lines; therefore, at the time of testing, promiscuous offspring had never experienced seminatural conditions, only their parents and ancestors had.
Mothers ranged in age from 17 to 37 years at the time of delivery, and the children from 5.2 to 10.7 years at the time of testing.
All patients had been discharged from the hospital, were stable at the time of testing and were tested a minimum of 1.4 years post-stroke (11 out of 14 were tested 3 years or more post-stroke, mean 7 years).
On a population basis, an increase in blood lead level from 2.4 to 10 μg/dL at the time of testing was associated with a decrease of 3.9 IQ points.
Compressive strength measured according to ASTM C39 (ASTM C39 2014) at the time of testing ranges from 22.4 to 24.3 MPs, with a mean value of 23.58 MPa.
Three cylinder specimens were used to measure concrete compressive strength according to ASTM C39 (ASTM C39 2014), resulting in a measured compressive strength (at the time of testing) ranging from 22.3 to 25.58 MPa, with a mean value of 22.84 MPa.
